Utilizing the aforementioned, a large body of evidence accumulated in the past years, marking lower ALT values as a reliable marker for sarcopenia and frailty, in large, heterogeneous patient populations [16,17,18,19]. This evidence concerns the gene GPT and sarcopenia.